Table 2 Reasons for rejection in 108 eyes (95 patients) on first-time application for funding of ranibizumab by the national health insurance system.
From: Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Reasons for rejection | Eyes, n (%) |
|---|---|
Diseases mimicking nAMD | 88 (81.5) |
Macular pucker/epiretinal membrane | 23 (21.3) |
Macular scarring | 17 (15.7) |
Dry-type AMD | 17 (15.7) |
Polypoidal choroidal vasculopathy | 14 (13.0) |
Pathological myopia | 4 (3.7) |
Macular hole | 3 (2.8) |
Cystoid macular oedema | 3 (2.8) |
Geographic atrophy | 1 (0.9) |
Central/branch retinal vein occlusion | 1 (0.9) |
Macular dystrophy | 1 (0.9) |
Macroaneurysm | 1 (0.9) |
Central serous chorioretinopathy | 1 (0.9) |
Administrative issues | 20 (18.5%) |
Poor quality, low resolution, or absence of FA/OCT | 12 (11.1) |
Corrected visual acuity <0.05 | 5 (4.6) |
Corrected visual acuity >0.5 | 1 (0.9) |
Inaccurate diagnosis in the operation consent | 1 (0.9) |
Misfiling the fellow normal eye | 1 (0.9) |
